Macrogenics (FRA:M55) ROE % Adjusted to Book Value : 153.80% (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics ROE % Adjusted to Book Value?

Macrogenics's ROE % for the quarter that ended in Sep. 2024 was 250.70%. Macrogenics's PB Ratio for the quarter that ended in Sep. 2024 was 1.63. Macrogenics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was 153.80%.

Macrogenics ROE % Adjusted to Book Value Historical Data

The historical data trend for Macrogenics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics ROE % Adjusted to Book Value Chart

Macrogenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-29.10

-11.24

-19.60

-23.50

-1.53

Macrogenics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															25.79	-26.46	-18.41	-61.69	153.80

Competitive Comparison of Macrogenics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Macrogenics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Macrogenics's ROE % Adjusted to Book Value falls into.

Macrogenics ROE % Adjusted to Book Value Calculation

Macrogenics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-6.06%	/	3.97
	=	-1.53%

Macrogenics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	250.70%	/	1.63
	=	153.80%

Macrogenics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Macrogenics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Macrogenics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (FRA:M55) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MGNX:USA

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).

Macrogenics Headlines

No Headlines